Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia

Journal Article · · J. Exp. Clin. Cancer Res.
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »; ; ; ; « less

Research Organization:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
DOE - Office Of Science; FOREIGN
OSTI ID:
1837306
Journal Information:
J. Exp. Clin. Cancer Res., Vol. 40
Country of Publication:
United States
Language:
ENGLISH

References (48)

TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors August 2017
2′- C -Cyano-2′-deoxy-1-β-d- arabino -pentofuranosylcytosine: A Novel Anticancer Nucleoside Analog that Causes Both DNA Strand Breaks and G 2 Arrest April 2001
SAMHD1 restricts HIV-1 infection in resting CD4+ T cells November 2012
Mechanisms of Multidrug Resistance in Cancer Chemotherapy May 2020
Replication of human herpesvirus type 6 (strain AJ) in JJHan cells grown in protein-free medium November 1995
The efficacy of sapacitabine in treating patients with acute myeloid leukemia September 2018
Promoter Methylation Regulates SAMHD1 Gene Expression in Human CD4+ T Cells March 2013
Features and development of Coot March 2010
What really matters - response and resistance in cancer therapy January 2018
The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells July 2013
HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase November 2011
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-?-d-ARABINO-Pentofuranosyl) cytosine) and itsN4-palmitoyl derivative (CS-682) July 1999
SAMHD1 protects cancer cells from various nucleoside-based antimetabolites May 2017
Substrates and Inhibitors of SAMHD1 January 2017
In vitro efficacy of forodesine and nelarabine (ara-G) in pediatric leukemia August 2011
Mechanism of allosteric activation of SAMHD1 by dGTP October 2013
Structural basis of cellular dNTP regulation by SAMHD1 September 2014
Phase I Clinical and Pharmacokinetic Study of Oral Sapacitabine in Patients With Acute Leukemia and Myelodysplastic Syndrome January 2010
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study November 2012
Phase 1/2 study of DFP‐10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia January 2019
The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1 October 2018
SAMHD1 modulates in vitro proliferation of acute myeloid leukemia-derived THP-1 cells through the PI3K-Akt-p27 axis May 2018
Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications September 2015
Molecular Basis for G 2 Arrest Induced by 2′- C -Cyano-2′-Deoxy-1-β-d- Arabino -Pentofuranosylcytosine and Consequences of Checkpoint Abrogation August 2005
Ataxia-telangiectasia and Rad3-related and DNA-dependent protein kinase cooperate in G 2 checkpoint activation by the DNA strand-breaking nucleoside analogue 2′- C -cyano-2′-deoxy-1-β-d- arabino -pentofuranosylcytosine January 2008
Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations November 2017
CNDAC-Induced DNA Double-Strand Breaks Cause Aberrant Mitosis Prior to Cell Death September 2019
Pharmacological Basis for Cladribine Resistance January 2003
Phaser crystallographic software July 2007
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells December 2011
Drug-adapted cancer cell lines as preclinical models of acquired resistance January 2019
Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays December 1983
Refinement of Macromolecular Structures by the Maximum-Likelihood Method May 1997
Development and biochemical characterization of a 2′-C-cyano-2′-deoxy-1-β-d-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080 January 1998
Deletion Mutants of Human Deoxycytidine Kinase mRNA in Cells Resistant to Antitumor Cytosine Nucleosides July 2001
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML August 2019
Doxorubicin-loaded human serum albumin nanoparticles overcome transporter-mediated drug resistance in drug-adapted cancer cells January 2019
Aicardi-Goutières Syndrome Gene and HIV-1 Restriction Factor SAMHD1 Is a dGTP-regulated Deoxynucleotide Triphosphohydrolase November 2011
SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine June 2020
SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia December 2016
A High-Throughput Enzyme-Coupled Assay for SAMHD1 dNTPase July 2015
Quantitation of endogenous nucleoside triphosphates and nucleosides in human cells by liquid chromatography tandem mass spectrometry March 2015
Mechanisms and therapeutic implications of hypermutation in gliomas April 2020
Overview of the CCP 4 suite and current developments March 2011
Phosphorylation of murine SAMHD1 regulates its antiretroviral activity December 2015
Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine January 2021
SAMHD1 can suppress lung adenocarcinoma progression through the negative regulation of STING January 2021
Expression of the novel tumour suppressor sterile alpha motif and HD domain‐containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma February 2021

Similar Records

Related Subjects